Trial Information

Summary: Study of the Efficacy of Using rEEG-Guided Treatment Compared to Generally Accepted Treatment in Subjects with Treatment Resistant Depression

This study is to evaluate the effectiveness of using rEEG technology to determine the most effective medication-based treatment for subjects with treatment-resistant depression in comparison to using generally accepted methods for selecting treatment. This is a 10-week study. Subjects will have a QEEG recorded and forwarded to the sponsor, who will analyze it utilizing their rEEG technology. Qualified subjects will be assigned by chance to either the experimental (rEEG guided) group, or the control group utilizing a more conventional approach to selecting a treatment. All medications to be selected will be FDA-approved.

Patient Inclusion Criteria:

• 18 years of age or older
• Diagnosis of Major Depressive Disorder
• Have failed treatment with three or more antidepressant treatments

Patient Exclusion Criteria:

• History of: closed head injury or other brain/head conditions
• Current diagnosis of seizure disorder, bipolar disorder, schizophrenia, dementia, mental retardation, or major depression with psychotic features
• Use of depot neuroleptics in last 12 months
• Recent history of or current substance abuse
• Women who are pregnant or breastfeeding
• No strong prediction by rEEG analysis for any particular medication class

For More Information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.